Ratings Seres Therapeutics, Inc.

Equities

MCRB

US81750R1023

Real-time Estimate Cboe BZX Other stock markets 13:39:26 2024-04-29 EDT			5-day change	1st Jan Change
0.913 ^USD	+10.67%		+46.61%	-34.59%

04-26	Foreign automakers eager for Chinese partners at Beijing auto show	RE
04-25	Battle for 'tech luxury' in China as EVs get smarter - and cheaper	RE

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SERES THERAPEUTICS, INC.	-34.59%	125M	C+
VERTEX PHARMACEUTICALS INCORPORATED	-2.41%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+1.74%	95.28B	B+
ARGENX SE	+1.46%	22.15B	B
BIONTECH SE	-15.68%	21.02B	B+
GENMAB A/S	-8.58%	18.15B	A-
WUXI APPTEC CO., LTD.	-38.74%	16.73B	A-
BEIGENE, LTD.	-13.01%	16.05B	B
NEUROCRINE BIOSCIENCES, INC.	+5.28%	13.68B	C+
SAREPTA THERAPEUTICS, INC.	+35.00%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes